- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01213979
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA) (PK-CIA-04)
June 26, 2013 updated by: Pharmacosmos A/S
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)(PK-CIA-04)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, aged more than 18 years.
- Weight above 50 kg.
- Subjects diagnosed with non-hematological malignancies (solid tumors only) receiving chemotherapy at least 1 day prior to screening and who are going to receive at least two more chemotherapy cycles.
- Hb < 12 g/dL.
- TfS <50%.
- Serum Ferritin <800 ng/ml.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Willingness to participate after informed consent.
Exclusion Criteria:
- Anaemia caused primarily by other factors than CIA.
- IV or oral iron treatment within 4 weeks prior to screening visit.
- Erythrypoietin treatment within 4 weeks prior to screening visit.
- Blood transfusion within 4 weeks prior to screening visit.
- Imminent expectation of blood transfusion on part of treating physician.
- Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
- Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulfate).
- Known hypersensitivity to any excipients in the investigational drug products.
- Subjects with a history of multiple allergies.
- Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALAT) > 3 times upper normal limit).
- History of Immunocompromise and/or history of Hepatitis B and/or C.
- Active acute or chronic infections (assessed by clinical judgement and if deemed necessary by investigator supplied with white blood cells (WBC) and C-reactive protein (CRP)).
- Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life (5 days) of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
- Planned elective surgery during the study.
- Participation in any other clinical study (except chemotherapy protocol) within 3 months prior to screening.
- Known intolerance to oral iron treatment.
- Untreated B12 or folate deficiency.
- Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1000 mg iron isomaltoside 1000 as intravenous infusion
|
1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
|
Active Comparator: 500 mg iron isomaltoside 1000 as bolus injection
|
500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total serum iron pharmakokinetic parameters
Time Frame: 24, 48 and 72 hours
|
24, 48 and 72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
October 1, 2010
First Submitted That Met QC Criteria
October 1, 2010
First Posted (Estimate)
October 4, 2010
Study Record Updates
Last Update Posted (Estimate)
June 27, 2013
Last Update Submitted That Met QC Criteria
June 26, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-PK-CIA-04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-hematological Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Senti BiosciencesNot yet recruitingAML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
AdaptimmuneRecruitingSolid and Hematological MalignanciesUnited States, Spain, Canada, United Kingdom
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
AstraZenecaParexelCompletedSolid and Hematological MalignanciesGermany
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
Clinical Trials on 1000 mg iron isomaltoside 1000
-
Pharmacosmos A/SCompletedInflammatory Bowel DiseaseDenmark
-
Seoul National University HospitalCompletedAnemia | Knee ArthropathyKorea, Republic of
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
University of MalayaRecruitingAnemia | Post Partum HemorrhageMalaysia
-
Pharmacosmos A/SBioStataCompletedAnaemia in Chronic Kidney DiseaseSweden, United Kingdom
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SCRO Max NeemanCompletedNon-anaemic Patients Undergoing Cardiac SurgeryDenmark
-
Universität des SaarlandesCompletedAnemia, Iron-DeficiencyGermany